Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response

Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response. There were 61 patients wi...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of rheumatology Ročník 43; číslo 8; s. 1566
Hlavní autoři:	Bauhammer, Jutta, Blank, Norbert, Max, Regina, Lorenz, Hanns-Martin, Wagner, Ulrich, Krause, Dietmar, Fiehn, Christoph
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Canada 01.08.2016
Témata:	Adult Aged Autoantibodies - analysis Dermatomyositis - drug therapy Dermatomyositis - immunology Female Humans Immunosuppressive Agents - therapeutic use Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - immunology Male Middle Aged Myositis - drug therapy Myositis - immunology Retrospective Studies Ribonucleoproteins - immunology Rituximab - therapeutic use Severity of Illness Index Treatment Outcome Young Adult INTERSTITIAL LUNG DISEASE ANTISYNTHETASE ANTIBODIES Ro52 Jo1 POLYMYOSITIS
ISSN:	0315-162X, 1499-2752, 1499-2752
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!